Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xeomin for Functional Thoracic Outlet Syndrome (Whiplash)
NCT05536570Phase 4Unknown
- Start
- Oct 2022
- Primary completion
- Apr 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of botulinum toxin type A in thoracic outlet syndrome (TOS). Primary endpoint: Pain Disability Questionnaire at 4 weeks. Status: unknown.
02
Drugs
botulinum toxin type A
03
Conditions
thoracic outlet syndrome (TOS)
Beyond the preview
Go deeper on NCT05536570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05536570.